아이데야, 4억 달러 규모의 바이오사이토젠과 ADC 계약 체결

Company

Category

거래/파트너링/M&A

Drug (API)

Indication

Official Announcement

https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-option-and-license-agreement-for-potential-first-in-class-b7h3ptk7-topo-i-payload-bispecific-adc-program-with-biocytogen-302210790.html

Firstword

https://firstwordpharma.com/story/5880861

Fierce Group

https://www.fiercebiotech.com/biotech/ideaya-eyeing-drug-combos-bags-option-biocytogen-bispecific-adc-400m-deal

Release Date

2024/07/31

TA

Type

Licensing

Approval DB

Class

Clinical DB

Licensing DB

Licensing DB (1) (Article DB)에 관계됨

Partnership DB

Target

Upload Date

2024/08/05

4 more properties

한글종합기사

Official Announcement

BioPharma Dive

BioSpace

Firstword

Fierce Group